Hyderabad-based company Bharat Biotech's covaxin has once again proved to be heavy on everyone. The Indian Council of Medical Research (ICMR) has claimed on Monday that Covaxin is also effective on the dangerous Delta Plus variant of Corona. According to ICMR, this has been revealed in the study of the institution. The National Institute of Virology (NIV) and ICMR have also collaborated in developing Covaxin.
At the same time, clinical trials can be done in Bangladesh to increase the international recognition of Covaxin. According to media reports, the trial was approved there on 18 July. According to a document of the Government of India, the government has approved financial assistance for this. The Indian government has facilitated the trial of the vaccine through its foreign embassies.
The government had proposed its trial in Bangladesh. A team was also sent by the Ministry of External Affairs to talk to the officials there. India has not yet sent Covaxin doses to Bangladesh. According to the data, India has sold 70 lakh doses of Covishield to Bangladesh so far and 33 lakh doses have been donated.
About a month ago, Bharat Biotech released data from the Phase III clinical trial of Covaxin. In this, the vaccine was reported to be 77.8% effective against all variants of the corona. The company had submitted the data to the Drug Controller General of India (DCGI). This was followed by a meeting of the Subject Expert Committee (SEC), in which the data was approved.
According to the company, Phase-3 trials were conducted on 25,800 people. In this, it was seen how much this vaccine protects against corona. Earlier, the National Institute of Health (NIH), America's top health research institute, had reported that Covaxin also shows an effect on alpha and delta variants.
Read More: Ayushmann Khurrana pays tribute to 'immortal artiste' Kishore Kumar on his birth anniversary
Like and Follow us on :